IDEXX Laboratories (WKN: 888210) IDXX

www.idexx.de/corporate/home.html

www.idexx.com/en/about-idexx/investors/


Kurzporträt

Manufactures animal health products

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets.

It operates through the following business segments: Companion Animal Group; Water; Livestock, Poultry, and Dairy; and Other.

The Companion Animal Group segment refers to diagnostic and information technology-based products and services for the veterinary market.

The Water segment includes water quality products for testing of certain microbiological water contaminants.

The Livestock, Poultry, and Dairy segment involves diagnostic, health-monitoring, and food safety testing products for livestock and poultry health, and dairy products.

The Other segment comprises products for the human point-of-care medical diagnostics market with the company's pharmaceutical product line and out-licensing arrangements.

IDEXX Laboratories was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

de.4-traders.com/IDEXX-LABORATORIES-9641/...pide&mots=idxx

Kurs aktuell etwas zurück gekommen. Immer noch ein interessantes Unternehmen.

de.marketscreener.com/IDEXX-LABORATORIES-9641/
Q3
www.marketscreener.com/...dexx-3Q-Earnings-Snapshot-27525291/

www.marketscreener.com/...dexx-4Q-Earnings-Snapshot-27948600/

www.marketscreener.com/...nd-Full-Year-2018-Results-27948509/

02/01/2019 | 06:53am EST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported fourth-quarter earnings of $85.6 million.
The Westbrook, Maine-based company said it had net income of 98 cents per share.

The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 90 cents per share.
The Animal diagnostic and health care company posted revenue of $549.4 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $545.6 million.
For the year, the company reported profit of $377 million, or $4.26 per share. Revenue was reported as $2.21 billion.
Idexx expects full-year earnings to be $4.66 to $4.78 per share, with revenue in the range of $2.38 billion to $2.42 billion.

www.marketscreener.com/...dexx-1Q-Earnings-Snapshot-28514373/

05/01/2019 | 06:45am EDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Wednesday reported first-quarter earnings of $102.7 million.
On a per-share basis, the Westbrook, Maine-based company said it had net income of $1.17.
The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.04 per share.
The Animal diagnostic and health care company posted revenue of $576.1 million in the period.
Idexx expects full-year earnings to be $4.76 to $4.88 per share, with revenue in the range of $2.38 billion to $2.42 billion.
Idexx shares have increased 25% since the beginning of the year. The stock has risen 19% in the last 12 months.
This story was generated by Automated Insights (automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at www.zacks.com/ap/IDXX
Automated Insights, source Associated Press News

www.marketscreener.com/...ondition-and-Results-of-O-29492368/

www.marketscreener.com/...dexx-3Q-Earnings-Snapshot-29489583/

Idexx: 3Q Earnings Snapshot

10/31/2019 | 06:46am EDT
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Thursday reported third-quarter net income of $108.8 million.
The Westbrook, Maine-based company said it had net income of $1.24 per share.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.13 per share.
The Animal diagnostic and health care company posted revenue of $605.3 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $597.4 million.
Idexx expects full-year earnings to be $4.72 to $4.78 per share, with revenue expected to be $2.4 billion.
Idexx shares have risen 47% since the beginning of the year. The stock has climbed 30% in the last 12 months.
This story was generated by Automated Insights (automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at www.zacks.com/ap/IDXX
Automated Insights, source Associated Press News

www.marketscreener.com/...dexx-4Q-Earnings-Snapshot-29920185/

Idexx: 4Q Earnings Snapshot

01/31/2020 | 06:59am EST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported fourth-quarter earnings of $90.5 million.
On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.04.
The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 91 cents per share.
The Animal diagnostic and health care company posted revenue of $605.4 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $599.9 million.
For the year, the company reported profit of $427.7 million, or $4.89 per share. Revenue was reported as $2.41 billion.
Idexx expects full-year earnings to be $5.42 to $5.58 per share, with revenue in the range of $2.62 billion to $2.66 billion.
Idexx shares have risen roughly 9% since the beginning of the year. The stock has increased 37% in the last 12 months.
This story was generated by Automated Insights (automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at www.zacks.com/ap/IDXX
Automated Insights, source Associated Press News

www.marketscreener.com/...nd-Full-Year-2019-Results-29920019/

Achieves revenue growth in Q4 of 10% on a reported and organic basis, driven by CAG Diagnostics recurring revenue reported and organic growth of 11%
Reports 19% year-over-year increase in Catalyst placements at new and competitive accounts in Q4, supporting full year growth of 16% in IDEXX's premium instrument installed base
Delivers full year EPS of $4.89, representing 15% growth on a reported basis and 21% on a comparable constant currency basis
Increases 2020 revenue guidance to $2,620 million - $2,655 million, reflecting consistent expectations for reported and organic revenue growth of 9% - 10.5%
Raises 2020 EPS outlook range by $0.12 to $5.42 - $5.58, reflecting expectations for continued strong operating trends, higher estimates for share-based compensation tax benefits and favorable adjustments to projected foreign exchange rates impacts

www.marketscreener.com/...dexx-1Q-Earnings-Snapshot-30502962/

Idexx: 1Q Earnings Snapshot
share with twitter share with LinkedIn share with facebook share via e-mail
0
04/30/2020 | 11:45am BST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Thursday reported first-quarter profit of $111.8 million.

On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.29.

The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.23 per share.

The Animal diagnostic and health care company posted revenue of $626.3 million in the period, missing Street forecasts. Three analysts surveyed by Zacks expected $631.8 million.

Idexx shares have risen slightly more than 4% since the beginning of the year. The stock has climbed 18% in the last 12 months.

This story was generated by Automated Insights (automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at www.zacks.com/ap/IDXX

Automated Insights, source Associated Press News

www.marketscreener.com/...dexx-2Q-Earnings-Snapshot-31029808/

dexx: 2Q Earnings Snapshot

07/31/2020 | 11:42am BST
WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported second-quarter profit of $148.9 million.

On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.72.

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.20 per share.

The Animal diagnostic and health care company posted revenue of $637.6 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $580 million.

Idexx shares have risen 43% since the beginning of the year. The stock has risen 31% in the last 12 months.

www.marketscreener.com/quote/stock/...ings-Snapshot-31639779/

Idexx: 3Q Earnings Snapshot

10/29/2020 | 10:51am GMT

WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Thursday reported third-quarter profit of $146.2 million.

On a per-share basis, the Westbrook, Maine-based company said it had profit of $1.69.

The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of $1.42 per share.

The Animal diagnostic and health care company posted revenue of $721.8 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $670.7 million.

Idexx shares have risen 62% since the beginning of the year. The stock has increased 59% in the last 12 months.

www.marketscreener.com/quote/stock/...arter-Results-31639565/

Achieves revenue growth of 19% on a reported basis and 18% on an organic basis driven by Companion Animal Group Diagnostics recurring revenue growth of 23% reported and 21% organic
High revenue growth supported by sustained strong global recovery in the pet healthcare market
Delivers EPS of $1.69, representing 36% growth on a reported basis and 47% on a comparable constant currency basis, reflecting benefits from high CAG Diagnostics recurring revenue gains and proactive cost controls

www.marketscreener.com/quote/stock/...ings-Snapshot-32334711/

4Q Earnings Snapshot
02/02/2021 | 11:49am GMT

WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Tuesday reported fourth-quarter earnings of $174.8 million.

The Westbrook, Maine-based company said it had net income of $2.01 per share.

The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of $1.43 per share.

The Animal diagnostic and health care company posted revenue of $720.9 million in the period, which also topped Street forecasts. Four analysts surveyed by Zacks expected $681.5 million.

For the year, the company reported profit of $581.8 million, or $6.71 per share. Revenue was reported as $2.71 billion.

Idexx expects full-year earnings to be $7.39 to $7.71 per share, with revenue in the range of $3.07 billion to $3.12 billion.

Idexx shares have decreased 1.5% since the beginning of the year. The stock has risen 74% in the last 12 months.

This story was generated by Automated Insights (automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at www.zacks.com/ap/IDXX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

www.marketscreener.com/quote/stock/...-2021-Outlook-32335507/

Bin jetzt auch dabei. Die Growth Story stimmt und mich hat der hohe Anteil an wiederkehrenden Umsätzen überzeugt. Da ich 3-5 Jahre Zeit mitbringe, ist das Investment ein No-Brainer  

www.marketscreener.com/quote/stock/...ings-Snapshot-36016661/

Idexx: Q2 Earnings Snapshot
07/30/2021 | 11:41am BST

WESTBROOK, Maine (AP) _ Idexx Laboratories Inc. (IDXX) on Friday reported second-quarter profit of $202.6 million.

On a per-share basis, the Westbrook, Maine-based company said it had profit of $2.34.

The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of $2.01 per share.

The Animal diagnostic and health care company posted revenue of $826.1 million in the period, also exceeding Street forecasts. Four analysts surveyed by Zacks expected $781.5 million.

Idexx expects full-year earnings to be $8.20 to $8.36 per share, with revenue in the range of $3.17 billion to $3.21 billion.

Idexx shares have climbed 41% since the beginning of the year. The stock has increased 92% in the last 12 months.

This story was generated by Automated Insights (automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on IDXX at www.zacks.com/ap/IDXX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

www.marketscreener.com/quote/stock/...-Results-of-O-36023448/

IDEXX Laboratories And Its Real Value

seekingalpha.com/article/...x-laboratories-and-its-real-value

IDEXX Laboratories steigert Gewinn und Umsatz im 4. Quartal und gibt Prognose für 2022 ab
02.02.2022 | 13:12

(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Mittwoch für das vierte Quartal einen Gewinn pro Aktie von $1,83, verglichen mit $1,63 im Vorjahr.

Die von Capital IQ befragten Analysten erwarteten $1,72.

Der Umsatz von $801,1 Millionen lag über dem Vorjahreswert von $720,9 Millionen. Die von Capital IQ befragten Analysten hatten mit 781,8 Mio. $ gerechnet.

Für das Jahr 2022 erwartet das Unternehmen einen Gewinn je Aktie zwischen 9,27 und 9,59 Dollar bei einem Umsatz von 3,5 bis 3,6 Milliarden Dollar.

de.marketscreener.com/kurs/aktie/...ose-fur-2022-ab-37720598/

IDEXX Laboratories Q1 Gewinnrückgang, Umsatzanstieg; Unternehmen senkt Ausblick für 2022
04.05.2022 | 13:20

(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Mittwoch für das erste Quartal einen Gewinn von $2,27 pro verwässerter Aktie, gegenüber $2,35 im Vorjahr.

Die von Capital IQ befragten Analysten hatten mit $2,24 gerechnet.

Der Umsatz für das Quartal, das am 31. März endete, lag bei 836,5 Mio. $, gegenüber 777,7 Mio. $ im Vorjahresquartal.

Die von Capital IQ befragten Analysten hatten $836,5 Millionen prognostiziert.

Für das Gesamtjahr 2022 rechnet das Tiergesundheitsunternehmen nun mit einem Gewinn je Aktie von 8,11 bis 8,35 Dollar, nachdem zuvor 9,27 bis 9,59 Dollar erwartet worden waren.

IDEXX rechnet für das Jahr 2022 mit einem Umsatz von 3,39 bis 3,47 Mrd. Dollar, nachdem zuvor 3,5 bis 3,57 Mrd. Dollar erwartet wurden.

Die Aktien des Unternehmens gaben im vorbörslichen Handel um 9% nach.

Kurs: 396.75, Veränderung: -39.21, Prozentuale Veränderung: -8.99

IDEXX Laboratories Q3 EPS, Umsatzanstieg; senkt EPS-Prognose für 2022
01.11.2022 | 12:30

(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Dienstag für das 3. Quartal einen Gewinn von $2,15 je verwässerter Aktie, gegenüber $2,03 im Vorjahr.

Die von Capital IQ befragten Analysten hatten $2,04 erwartet.

Der Umsatz für das Quartal, das am 30. September endete, lag bei 841,7 Millionen Dollar, verglichen mit 810,4 Millionen Dollar im Vorjahr.

Die von Capital IQ befragten Analysten hatten mit $830 Millionen gerechnet.

Für das Gesamtjahr 2022 rechnet das Unternehmen nun mit einem Gewinn je Aktie von 7,74 bis 7,98 Dollar. Dies steht im Vergleich zu der vorherigen Prognose von $7,77 bis $8,05.

Außerdem erwartet das Unternehmen für 2022 einen Umsatz von 3,33 bis 3,37 Milliarden Dollar. Zuvor waren es 3,31 bis 3,39 Milliarden Dollar.

de.marketscreener.com/kurs/aktie/...ognose-fur-2022-42164675/

de.marketscreener.com/kurs/aktie/...d-Umsatzanstieg-42908837/

IDEXX Laboratories: Q4-Ergebnis und Umsatzanstieg

(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Montag für das vierte Quartal einen bereinigten Gewinn von $2,07 je verwässerter Aktie, nach $1,81 im Vorjahr.

Die von Capital IQ befragten Analysten hatten mit $1,92 gerechnet.

Der Umsatz für das Quartal, das am 31. Dezember endete, belief sich auf 828,6 Millionen Dollar, verglichen mit 801,1 Millionen Dollar vor einem Jahr.

Die von Capital IQ befragten Analysten hatten $ 820,9 Millionen erwartet.

Das Unternehmen sagte, es erwarte für das Gesamtjahr 2023 einen Gewinn von 9,27 bis 9,75 Dollar je verwässerter Aktie. Die von Capital IQ befragten Analysten erwarten $9,47.

Das Unternehmen erwartet für das Jahr einen Umsatz von 3,60 bis 3,69 Milliarden Dollar. Die von Capital IQ befragten Analysten rechnen mit $3,62 Milliarden.

de.marketscreener.com/kurs/aktie/...n-Umsatzanstieg-43711603/

IDEXX Laboratories Q1 bereinigter Gewinn, Umsatzanstieg
02.05.2023 | 14:05

(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Dienstag für das erste Quartal einen Gewinn von 2,55 Dollar pro verwässerter Aktie, nach 2,27 Dollar pro Aktie vor einem Jahr.

Die von Capital IQ befragten Analysten hatten ein EPS von $2,38 erwartet.

Der Umsatz für das Quartal, das am 31. März endete, betrug 900,2 Millionen Dollar, verglichen mit 836,5 Millionen Dollar vor einem Jahr. Die von Capital IQ befragten Analysten hatten $890,6 Millionen erwartet.

Das Unternehmen sagte, es erwarte 2023 ein EPS von $9,33 bis $9,75. Die von Capital IQ befragten Analysten erwarten $9,48. Der Umsatz für das Jahr wird voraussichtlich zwischen $3,62 Milliarden und $3,70 Milliarden liegen. Die von Capital IQ befragten Analysten erwarten $3,66 Milliarden.

de.marketscreener.com/kurs/aktie/...se-2023-gesenkt-45209388/

IDEXX Laboratories Q3 vergleichbares Ergebnis, Umsatzanstieg; Umsatzprognose 2023 gesenkt
Am 01. November 2023 um 12:21 Uhr

(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Mittwoch für das 3. Quartal einen vergleichbaren Gewinn von $2,50 pro Aktie, gegenüber $2,15 im Vorjahr.
Die von Capital IQ befragten Analysten hatten $2,37 erwartet.

Der Umsatz für das Quartal, das am 30. September endete, betrug 915,5 Millionen Dollar, verglichen mit 841,7 Millionen Dollar im Vorjahr.

Die von Capital IQ befragten Analysten hatten 927,3 Millionen Dollar erwartet.

Für das Jahr 2023 rechnet das Unternehmen für Haustiermedizin nun mit einem Gewinn je Aktie von 9,74 bis 9,90 Dollar, nachdem zuvor 9,64 bis 9,90 Dollar erwartet worden waren. Die von Capital IQ befragten Analysten rechnen mit $9,78. Das Unternehmen rechnet nun mit einem Umsatz von 3,64 bis 3,65 Mrd. $, nachdem es zuvor eine Spanne von 3,66 bis 3,72 Mrd. $ angekündigt hatte. Die von Capital IQ befragten Analysten rechnen mit $3,68 Milliarden.

de.marketscreener.com/kurs/aktie/...n-Umsatzanstieg-45883604/

IDEXX Laboratories: Q4-Gewinn, Umsatzanstieg
Am 05. Februar 2024 um 13:22 Uhr
(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Montag für das vierte Quartal einen Gewinn von $2,32 pro verwässerter Aktie, gegenüber $2,05 im Vorjahr.
Die von Capital IQ befragten Analysten hatten $2,12 erwartet.

Der Umsatz für das Quartal, das am 31. Dezember endete, betrug 901,6 Millionen Dollar, verglichen mit 828,6 Millionen Dollar im Vorjahr.

Die von Capital IQ befragten Analysten hatten mit $890,6 Millionen gerechnet.

Das Unternehmen sagte, es erwarte 2024 einen Gewinn von 10,84 bis 11,33 Dollar pro Aktie bei einem Umsatz von 3,93 bis 4,04 Milliarden Dollar. Die von Capital IQ befragten Analysten erwarten einen Gewinn von $10,93 pro Aktie bei einem Umsatz von $3,97 Milliarden.

www.finanznachrichten.de/...ates-trims-annual-outlook-020.htm

ROUNDUP: IDEXX Laboratories Q1 Profit Up, Beats Estimates; Trims Annual Outlook

WASHINGTON (dpa-AFX) - (Adds outlook)

For the full year, IDEXX Laboratories, Inc. (IDXX) has revised down its annual outlook.

The company now expects net income per share of $10.82 to $11.20 against previous outlook of $10.84 to $11.33 per share, citing around $0.11 negative foreign exchange rate impact.

Analysts, on average, expect the company to post income per share of $11.12, for the year.

Revenue is projected to be in the range of $3.895 billion to $3.965 billion versus its earlier view of $3.930 billion to $4.04 billion. The Street estimate stands at $3.99 billion.

This new revenue outlook includes a $35 million negative impact from the recent strengthening of the dollar and a reduction of 1 percent to the high end of the organic revenue growth range to reflect near-term moderation in the U.S. clinical visit growth trends.

Q1 Results:

IDEXX reported a profit for its first quarter that increased from the same period last year and beat the Street estimates.

The company's bottom line totaled $235.58 million, or $2.81 per share. This compares with $214.05 million, or $2.55 per share, in last year's first quarter.

Analysts on average had expected the company to earn $2.67 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 7.1% to $964.10 million from $900.20 million last year.

IDEXX Laboratories Inc earnings at a glance (GAAP) :

-Earnings (Q1): $235.58 Mln. vs. $214.05 Mln. last year. -EPS (Q1): $2.81 vs. $2.55 last year. -Revenue (Q1): $964.10 Mln vs. $900.20 Mln last year.

-Guidance: Full year EPS guidance: $10.82 - $11.20 Full year revenue guidance: $3,895 - $3,965 Mln

Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX

de.marketscreener.com/kurs/aktie/...msatzprognose-f-47566651/

Am 06. August 2024 um 13:26 Uhr

(MT Newswires) -- IDEXX Laboratories (IDXX) meldete am Dienstag für das 2. Quartal einen bereinigten Gewinn von 3,02 Dollar je verwässerter Aktie, nach 2,63 Dollar im Vorjahr.
Die von Capital IQ befragten Analysten hatten $2,87 erwartet.

Der Umsatz für das Quartal, das am 30. Juni endete, lag bei $1 Milliarde, verglichen mit $943,6 Millionen im Vorjahr.

Die von Capital IQ befragten Analysten hatten mit $1 Milliarde gerechnet.

Das Unternehmen teilte mit, dass es nun für 2024 einen Umsatz von 3,89 bis 3,95 Mrd. $ erwartet, gegenüber 3,9 bis 3,97 Mrd. $ zuvor. Die von Capital IQ befragten Analysten rechnen mit 3,94 Milliarden Dollar.

IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket
Zacks Equity Research
Thu, October 31, 2024 at 4:07 PM GMT+1 5 min read


In This Article:
IDXX
-9.38%
IDEXX Laboratories, Inc. IDXX posted third-quarter 2024 earnings per share (EPS) of $2.80, up 10.7% year over year. The figure surpassed the Zacks Consensus Estimate by 4.1%.

Comparable constant-currency EPS of $2.79 improved 12% year over year.

Find the latest EPS estimates and surprises on Zacks Earnings Calendar.

Following the earnings announcement, IDXX stock fell 3.1% at the pre-market trading today.

IDEXX’s Revenues in Detail
Quarterly revenues increased 6.6% year over year (up 6% organically) to $975.5 million. The reported figure missed the Zacks Consensus Estimate marginally by 0.4%.

weiter hier:

finance.yahoo.com/news/idxx-q3-earnings-top-24-150700473.html

de.marketscreener.com/kurs/aktie/...hfolger-ernannt-48428623/